Literature DB >> 3952123

Studies of the relationship between molecular structure and hallucinogenic activity.

D E Nichols.   

Abstract

The nature of the stereochemistry and aromatic ring substituents and their importance to biological activity for phenethylamine-type hallucinogens is presented. The possibility of a hydrophobic site to bind to the 4-substituent and its likely geometry is described. A brief discussion of the structure-activity relationships for tryptamines such as psilocin and DMT is also given, with comments about the stereochemistry of alpha-methyltryptamines. Evaluation of a series of N(6)-alkyl-nor-LSD derivatives indicated that selected members such as N(6)-ethyl, allyl and propyl were as potent as, if not more potent than LSD, both in a two-lever drug discrimination assay in rats, and in man. N(6)-alkyl groups longer than n-propyl, such as n-butyl or 2-phenethyl, gave compounds that were greatly reduced in activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3952123     DOI: 10.1016/0091-3057(86)90362-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  2 in total

1.  Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Simon P Elliott; Jason Wallach; Tristan Colestock; Timothy E Burrow; Stephen J Chapman; Alexander Stratford; David E Nichols; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2016-06-06       Impact factor: 3.345

2.  Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.

Authors:  Amy J Eshleman; Michael J Forster; Katherine M Wolfrum; Robert A Johnson; Aaron Janowsky; Michael B Gatch
Journal:  Psychopharmacology (Berl)       Date:  2013-10-19       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.